These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16798551

  • 21. Two novel missense and one novel nonsense CFTR mutations in Iranian males with congenital bilateral absence of the vas deferens.
    Radpour R, Gourabi H, Gilani MA, Dizaj AV, Rezaee M, Mollamohamadi S.
    Mol Hum Reprod; 2006 Nov; 12(11):717-21. PubMed ID: 16973827
    [Abstract] [Full Text] [Related]

  • 22. Future pharmacological treatment of cystic fibrosis.
    Zeitlin PL.
    Respiration; 2000 Nov; 67(4):351-7. PubMed ID: 10940786
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
    Cheung JC, Deber CM.
    Biochemistry; 2008 Feb 12; 47(6):1465-73. PubMed ID: 18193900
    [Abstract] [Full Text] [Related]

  • 25. Genistein modifies the activation kinetics and magnitude of phosphorylated wild-type and G551D-CFTR chloride currents.
    Bulteau-Pignoux L, Dérand R, Métayé T, Joffre M, Becq F.
    J Membr Biol; 2002 Aug 01; 188(3):175-82. PubMed ID: 12181609
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Molecular studies of CFTR interacting proteins.
    Wang S, Li M.
    Pflugers Arch; 2001 Aug 01; 443 Suppl 1():S62-4. PubMed ID: 11845305
    [Abstract] [Full Text] [Related]

  • 31. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC, De Boeck K, Amaral MD.
    Pharmacol Ther; 2015 Jan 01; 145():19-34. PubMed ID: 24932877
    [Abstract] [Full Text] [Related]

  • 32. Defective formation of PKA/CnA-dependent annexin 2-S100A10/CFTR complex in DeltaF508 cystic fibrosis cells.
    Borthwick LA, Riemen C, Goddard C, Colledge WH, Mehta A, Gerke V, Muimo R.
    Cell Signal; 2008 Jun 01; 20(6):1073-83. PubMed ID: 18346874
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [From the laboratory to the clinic: CFTR and the therapeutic options for cystic fibrosis].
    Mayol J, Alvarez de Arcaya Vicente A, Arbeo Escolar AM, Peña Soria MJ, Alvarez Fernández-Represa J.
    An Med Interna; 2000 Feb 01; 17(2):92-8. PubMed ID: 10829466
    [Abstract] [Full Text] [Related]

  • 35. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR.
    Du K, Sharma M, Lukacs GL.
    Nat Struct Mol Biol; 2005 Jan 01; 12(1):17-25. PubMed ID: 15619635
    [Abstract] [Full Text] [Related]

  • 36. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
    Loo TW, Bartlett MC, Clarke DM.
    Biochemistry; 2009 Oct 20; 48(41):9882-90. PubMed ID: 19761259
    [Abstract] [Full Text] [Related]

  • 37. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability.
    Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, Bear CE.
    Mol Pharmacol; 2009 Jun 20; 75(6):1430-8. PubMed ID: 19339490
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.